Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service CGM & insulin pump management cases in Massachusetts: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (248 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 121 | 8,369 | 28% |
| 2020 | 121 | 7,668 | 30% |
| 2021 | 165 | 12,520 | 32% |
| 2022 | 197 | 15,953 | 35% |
| 2023 | 223 | 19,759 | 38% |
| 2024 | 240 | 25,322 | 39% |
| 2025 from claims | – | 30,801 28,267–32,587 | 40% |
| 2026 forecast | – | 34,367 30,238–39,658 | 39% |
| 2027 forecast | – | 37,822 32,333–45,072 | 40% |
| 2028 forecast | – | 41,622 34,730–50,965 | 40% |
| 2029 forecast | – | 45,803 37,411–57,442 | 40% |
| 2030 forecast | – | 50,404 40,380–64,592 | 40% |
CGM setup and interpretation codes identify who prescribes diabetes technology. Professional codes (what the surgeon bills): CPT 95249, 95250, 95251.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 16% of the cases CMS names in Massachusetts; 121 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 36% hospital outpatient, 64% office. The share outside the hospital has moved −14 pts since 2019.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 496 | 58,834+16%/yr | +16%/yr | 31.7 | 89% | 98,600 in 2030+9%/yr |
| New Jersey | 303 | 39,418+16%/yr | +16%/yr | 37.1 | 99% | 69,600 in 2030+10%/yr |
| Pennsylvania | 334 | 37,842+26%/yr | +26%/yr | 27.2 | 80% | 63,900 in 2030+9.1%/yr |
| Connecticut | 137 | 10,569+19%/yr | +19%/yr | 31.3 | 79% | 18,600 in 2030+9.9%/yr |
| New Hampshire | 60 | 7,226+35%/yr | +35%/yr | 31.5 | 56% | 14,600 in 2030+12%/yr |
| Maine | 30 | 2,429+36%/yr | +36%/yr | 15.1 | 18% | 4,270 in 2030+9.9%/yr |
| Rhode Island | 19 | 1,789+12%/yr | +12%/yr | 19.2 | 87% | 3,570 in 2030+12%/yr |
| Vermont | 14 | 1,742+68%/yr | +68%/yr | 15.1 | 23% | 4,210 in 2030+16%/yr |
CGM & insulin pump management in every state, and its device makers · Every procedure market in Massachusetts · Every state · Compare with New York
Abbott leads with 65% of company spending on these surgeons in 2025, +16 pts on 2024.
In 2025, 8 companies reported engagement with Massachusetts’s surgeons worth $198K in consulting, speaking, meals and travel tied to these products, about $824 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 37 clearances and approvals in the category, 33 recalled product lines (8 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.